Corcept Therapeutics Q3 2023 EPS $0.28 Down From $0.30 YoY, Revenue $123.6M Beats $119.678M Estimate
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics reported Q3 2023 earnings per share (EPS) of $0.28, down from $0.30 year over year (YoY). However, the company's revenue of $123.6M beat the estimate of $119.678M.
November 01, 2023 | 8:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Corcept Therapeutics' Q3 2023 EPS decreased YoY, but revenue surpassed estimates. This mixed result could lead to uncertain market reactions.
Corcept Therapeutics' EPS fell YoY, which could negatively impact the stock. However, the company's revenue beat estimates, which is a positive signal and could offset the negative impact of the EPS decrease. The net effect on the stock price is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100